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OBJECTIVE—Insulin deﬁciency in type 1 diabetes and in
rodent autoimmune diabetes models is caused by -cell–speciﬁc
killing by autoreactive T-cells. Less is known about -cell num-
bers and phenotype remaining at diabetes onset and the fate of
other pancreatic endocrine cellular constituents.
RESEARCH DESIGN AND METHODS—We applied multi-
color ﬂow cytometry, confocal microscopy, and immunohisto-
chemistry, supported by quantitative RT-PCR, to simultaneously
track pancreatic endocrine cell frequencies and phenotypes
during a T-cell–mediated -cell–destructive process using two
independent autoimmune diabetes models, an inducible autoan-
tigen-speciﬁc model and the spontaneously diabetic NOD mouse.
RESULTS—The proportion of pancreatic insulin-positive -cells
to glucagon-positive -cells was about 4:1 in nondiabetic mice.
Islets isolated from newly diabetic mice exhibited the expected
severe -cell depletion accompanied by phenotypic -cell
changes (i.e., hypertrophy and degranulation), but they also
revealed a substantial loss of -cells, which was further con-
ﬁrmed by quantitative immunohistochemisty. While maintaining
normal randomly timed serum glucagon levels, newly diabetic
mice displayed an impaired glucagon secretory response to
non–insulin-induced hypoglycemia.
CONCLUSIONS—Systematically applying multicolor ﬂow cy-
tometry and immunohistochemistry to track declining -cell
numbers in recently diabetic mice revealed an altered endocrine
cell composition that is consistent with a prominent and unex-
pected islet -cell loss. These alterations were observed in
induced and spontaneous autoimmune diabetes models, became
apparent at diabetes onset, and differed markedly within islets
compared with sub–islet-sized endocrine cell clusters and among
pancreatic lobes. We propose that these changes are adaptive in
nature, possibly fueled by worsening glycemia and regenerative
processes. Diabetes 58:1175–1184, 2009
A
lthough much has been learned about -cell
development and -cell biology and function in
vitro (using isolated pancreatic islets), studies
designed to examine -cell phenotype in vivo
have suffered from technical limitations. For instance,
currently available techniques to quantify pancreatic -cell
mass rely on laborious histomorphometric techniques (1)
or on assumptions that -cell mass correlates with -cell
function (stimulated C-peptide release) (2) or total pan-
creatic insulin content (3,4). Furthermore, quantifying the
different endocrine islet cellular constituents by staining
for the hormones produced (i.e., glucagon by -cells,
insulin by -cells, somatostatin by -cells, and pancreatic
polypeptide by PP-cells) has to date been challenging,
relying again mostly on histomorphometry, and automated
image processing setups typically allow only single-param-
eter analysis (5,6).
Although preparative ﬂuorescence-activated cell sort-
ing of islet -cells has been attempted (7–10), wider
application has been limited by the lack of islet endo-
crine cell surface markers and insufﬁcient resolution by
autoﬂuorescence, especially in species other than rats
(11). Fluorescence reagents with islet granule afﬁnity to
identify -cells in both mice (12) and humans (13) have
limited utility, presumably because -cells are degranu-
lated by hyperglycemia. Other methods, such as quantita-
tive (q)RT-PCR and analytical multicolor/multiparameter
ﬂow cytometry, capable of precise phenotypic and
functional assessment, have been hampered by both the
notorious difﬁculty to reliably prepare pancreatic RNA
(14) and the fact that the pancreas is a heterogeneous
organ comprised of irregularly intermixed exocrine and
endocrine tissues. Even so-called “puriﬁed” isolated
pancreatic islets from naïve mice (or other mammals)
represent a multitude of specialized cell types (15),
which is further complicated in animals with autoim-
mune diabetes when abundant inﬂammatory cells in-
vade the islets (16).
Recognizing these limitations, we adapted ﬂow cytom-
etry techniques for pancreatic studies and, together with
qRT-PCR, confocal immunoﬂuorescence microscopy, and
quantitative immunohistochemistry, characterized the
pancreatic endocrine islet cell components in naïve and
recently diabetic mice. We now report that pancreatic
islets isolated from mice developing T-cell–mediated
-cell–speciﬁc autoimmune diabetes demonstrate an un-
expected glucagon-positive -cell loss roughly commensu-
rate with the expected -cell loss.
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Rat insulin promoter (Rip) lymphocytic choriomeningitis virus (LCMV)-
glycoprotein (GP)  Rip-CD80 bitransgenic mice (17), NOD mice, and fully
backcrossed NOD-Rag1 null or NOD-SCID mice (both from Jackson Labs)
were used as autoimmune diabetes models and controls, respectively. GP-
speciﬁc, T-cell receptor–(TCR) transgenic mice—p14 strain (18), Rag1 null—
were used as a source of monoclonal, -cell–speciﬁc CD8
 T-cells. All mice
were housed at the Division of Veterinary Resources, National Institutes of
Health, in accordance with the guidelines set forth by the committee on the
care and use of laboratory animals on a protocol approved by the animal care
and use committee of the National Institute of Diabetes and Digestive and
Kidney Diseases.
CD8
 T-cell puriﬁcation and in vitro T-cell activation. TCR-transgenic
CD8
 T-cells (P14 strain, Rag1 null) were puriﬁed by immunodepleting spleen
and lymph node cells expressing I-A
b, CD11b, and NK1.1, yielding cells that
were 86–95% CD8
 T-cells. These cells (0.5  10
6/cm
2) were stimulated for
3–4 days in the presence of -interferon–pretreated ﬁbroblasts incubated with
the GP agonist peptide (LCMV-GP amino acids 33–41 at 0.1 mol/l for 1 h).
Cultures were supplemented with interleukin-2 (2 ng/ml) after 48 h. On day 3
of culture, 98% of viable cells were CD8
 TCR-transgenic by ﬂow cytometry
(data not shown).
Diabetes induction and diagnosis. We have studied a transgenic mouse
model of immune-mediated -cell destruction and diabetes that relies on the
mouse -cells expressing the LCMV GP under the control of Rip. If such mice
are infected with LCMV, the antiviral immune response also leads to fulminant
diabetes. We have modiﬁed that system by creating bitransgenic mice such
that their -cells also speciﬁcally express the T-cell costimulatory ligand CD80
(4). These mice are highly susceptible to autoimmune -cell destruction
induced by immunizing with the GP antigen, a model system we’ve named
experimental autoimmune diabetes (EAD) (17). For these studies, we adop-
tively transferred in vitro activated LCMV-GP–speciﬁc cytotoxic T-lympho-
cytes (CTLs; 10
6 per mouse) to the Rip-CD80
GP
 recipients. This EAD
system initiates a slowly progressive anti–-cell–speciﬁc immune destructive
process such that diabetes develops 53 	 9 days after CTL transfer. At 
4
weeks after CTL transfer, nondiabetic mice were checked daily for diabetes
development, indicated by glycosuria and conﬁrmed when blood glucose
readings were 14 mmol/l.
Islet isolation and islet cell ﬂow cytometry. Pancreatic islets were
isolated by standard techniques. Brieﬂy, pancreata were inﬂated via bile duct
cannulation and retrograde pancreatic duct injection of 3–4 ml of ice-cold
collagenase type V (1 mg/ml in Hank’s balanced salt solution). After digestion
(37°C, 14 min), pancreata were dispersed by aspirating through a 14-G needle,
ﬁltered through a metal strainer (0.8 mm), and subjected to buoyant density
gradient centrifugation (14–15% Optiprep; Accurate Chemicals, Westbury,
NY). After islets were carefully picked, the remaining viable pancreatic cells
were also collected. These cells containing sub–islet-sized endocrine clusters
and single endocrine cells were termed islet-depleted cells.
Isolated islets (and islet-depleted cells) were dissociated into a single-cell
suspension by gentle pipetting after washing in 2 mmol/l EDTA/PBS and
incubating for 10 min at ambient temperature in Ca
2-free PBS supplemented
with 0.025% trypsin. Dissociated islet cells prepared from pre-diabetic or
diabetic mice were stained for CD45 to identify inﬁltrating lymphocytes,
followed by washing, immediate ﬁxation, and permeabilization (4% parafor-
maldehyde, 0.1% saponin/PBS, 30 min). After removing paraformaldehyde by
washing in 0.1% saponin/1% BSA/PBS, islet cells were stained intracytoplas-
mically for 30 min with antibodies to insulin (guinea pig; Dako), pancreatic
polypeptide (rabbit; LabVision, Fremont, CA), and two mouse IgG1 monoclo-
nal antibodies speciﬁc for glucagon (K79bB10; Sigma) and somatostatin
(SOM018; antibody core facility, Beta Cell Biology Consortium, Antibody
Care Unit, Målov, Denmark). Simultaneous staining using both mouse IgG1
antibodies required Invitrogen’s Zenon (pre)labeling technology (Paciﬁc Blue,
AlexaFluor488). Highly cross-absorbed, second-step polyclonal antibodies,
anti–guinea pig Cy5, and anti-rabbit PE were from Jackson ImmunoResearch.
After the ﬁnal wash in 1% BSA/saponin, cells were postﬁxed in 1% parafor-
maldehyde and acquired using a CyAn ADP ﬂow cytometer (Beckman-
Coulter) using Summit version 4.3 software. Electronic gating was set to
include viable cells based on forward light scatter versus side light scatter.
The doublet-exclusion gating setup diminished nondissociated islet cell
couplets based on pulse width versus total signal area (linear scale) by

20-fold, yet they did not signiﬁcantly alter the relative endocrine cell
frequencies and the calculated cell ratios (supplemental Fig. 1, available in an
online appendix at http://diabetes.diabetesjournals.org/cgi/content/full/db08-
0616/DC1).
Immunoﬂuorescence and immunohistochemistry. Consecutive formalin-
ﬁxed parafﬁn-embedded sections (6 m) were hematoxylin and eosin stained
or subjected to immunostaining. Brieﬂy, after blocking with 2% BSA/1%
donkey serum and blocking reagent (M.O.M. kit; Vector, Burlingame, CA),
primary antibodies (same as described for ﬂow cytometry above, except for
the rabbit–anti-glucagon antibody [Dako]) were reacted overnight at 4°C,
washed three times (5 min, PBS 0.1% BSA, 0.1% Tween 20), and then stained
for 1 h using anti–guinea pig Cy3 (Jackson ImmunoResearch), anti-rabbit
AlexaFluor488, and anti-mouse AlexaFluor647 (Invitrogen) polyclonal anti-
bodies and counterstained with 46-diamidino-2-phenylindole (5 min).
Fluorescence analysis was performed on a Zeiss LSM 510 confocal
microscope using Zeiss LSM 510 Meta software (Carl Zeiss Microimaging,
Thornwood, NY).
B A C
FIG. 1. Pancreatic islet hormone-secreting cell subsets as assessed by immunoﬂuorescence and ﬂow cytometry. A: Pancreas section from a naïve
C57BL/6 mouse simultaneously stained for the three major endocrine cell subsets: insulin positive (-cells, red), glucagon positive (-cells,
green), and somatostatin positive (-cells, dark blue). Nuclei are shown in turquoise. Magniﬁcation 400. B: Islet endocrine cells by ﬂow
cytometry. Handpicked pancreatic islets isolated from one naïve C57BL/6 mouse were dissociated into a single-cell suspension and intracyto-
plasmically stained for insulin (red), glucagon (green), and somatostatin (blue). All other islet components (e.g., other endocrine, endothelial
cells) and residual exocrine cells are depicted in gray. For presentation purposes, insulin-, glucagon-, and somatostatin-positive endocrine cell
subsets (typically making up 
80% of healthy islets) were normalized to 100%. C: Quantitative analysis of islet cell subsets of naïve C57BL/6 mice
by ﬂow cytometry (f) and immunoﬂuorescence (u). For ﬂow cytometry, >10,000 events of dissociated and stained islet cells per mouse were
acquired. Frequencies (means  SE, n  5 mice) were: insulin positive 73.5  2.4%, glucagon positive 19.2  1.9%, somatostatin positive 5.5 
0.6%, and pancreatic polypeptide positive 1.7  0.5%. For immunoﬂuorescence, the three major endocrine cell subsets were quantiﬁed by
independent, triplicate, or quadruplicate scorings (>350 endocrine cells were counted of at least 12 randomly selected islets). Their frequencies
(means  SE, n  3 mice) were 76.7  1.1%, 17.3  3.3%, and 5.9  4.0% for insulin-, glucagon-, and somatostatin-positive cells, respectively. Gcg,
glucagon; Ins, insulin; Ppy, pancreatic polypeptide; Sst, somatostatin. (A high-quality digital representation of this ﬁgure is available in the online
issue.)
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immediately ﬁxed in 10% formalin. Formalin-ﬁxed parafﬁn-embedded sections
were antibody stained for insulin (Dako) or glucagon (Sigma) as above and
then reacted with diaminobenzidine staining kits (Vector Labs) and counter
stained with hematoxylin and eosin. Sections had an average tissue area of 72
mm
2 (63 mm
2 for diabetic pancreata), and the cumulative tissue area was
scored from 3–7 sections spatially separated by 200 m (surface-area range
studied: 154–648 mm
2 per pancreas). Slides were scanned and analyzed using
a Scanscope CS system with ImageScope software (Aperio Technologies,
Vista, CA). The insulin-positive -cell– and glucagon-positive -cell mass was
calculated from the sections by fractional cell staining over total pancreas
area for insulin- and glucagon-positive cells, respectively.
Stimulated glucagon secretion and quantiﬁcation. Glucagon secretory
responses to 2-deoxy-glucose (2-DG) were carried out as previously described
(19). Brieﬂy, 200 l retro-orbital blood was collected from newly diabetic and
age- and sex-matched naïve nondiabetic Rip-CD80
GP
 mice. After fasting
the animals overnight, two additional blood samples were taken from each
mouse before and, as a terminal procedure, 15 min after injecting the glucose
analog 2-DG (500 mg/kg i.p.). Serum was collected and stored frozen at 70°C.
Serum glucagon concentrations were determined using radioimmunoassay
(Millipore, St. Charles, MO).
Statistical analysis. An independent Student’s t test (one-tailed) was chosen
to test the signiﬁcance of deviations between data sets (endocrine cell
numbers or ratios). All data were displayed as the means 	 SE.
RESULTS
Although hormone-producing cells can be visualized by
multicolor immunoﬂuorescence (Fig. 1A), we sought to
more objectively quantify isolated pancreatic islets’ endo-
crine cell frequencies using intracytoplasmic, multicolor
ﬂow cytometry to simultaneously detect insulin-, gluca-
gon-, somatostatin-, and in some cases pancreatic polypep-
tide–positive cells. Figure 1B and supplemental Fig. 1
illustrate the detailed multiparameter ﬂow cytometry re-
sults of an islet cell suspension from naïve C57BL/6 mice.
We observed no overlap between the different endocrine
cell subsets, thus conﬁrming mature endocrine cells’
known lineage separation (i.e., each endocrine cell pro-
duces only one hormone). Artifactual dual-hormone stain-
ing resulting from heterogeneous endocrine cell couplets
was eliminated by routinely applying doublet-exclusion
gating strategies. We validated the ﬂow cytometry tech-
nique by comparing adult C57BL/6 mouse endocrine cell
subset frequencies determined using ﬂow cytometry and
immunoﬂuorescence and obtained quite concordant re-
sults (Fig. 1C) that were also consistent with published
data (20,21).
Next, using our -cell antigen-speciﬁc EAD model (17),
we tracked insulin-positive endocrine cell optical proper-
ties by ﬂow cytometry, and we tracked their abundance by
immunoﬂuorescence or immunohistochemistry, ﬂow cy-
tometry, and qRT-PCR during the islet inﬂammatory pro-
cess leading to diabetes. Flow cytometry revealed
markedly altered optical and staining properties displayed
by the insulin-staining -cells remaining at diabetes onset
(Fig. 2). Of particular note, some but not all -cells
remaining in diabetic mice are larger (or hypertrophic)
compared with naïve mouse -cells (Fig. 2A). In addition,
virtually all diabetic mouse -cells displayed reduced
granularity (i.e., decreased side light scatter) (Fig. 2B),
strongly suggesting a diminished cytoplasmic insulin gran-
ule content (degranulation). Coincident with these optical
changes, we found that diabetic mouse -cells’ insulin
staining intensity was less than that observed from naïve
mouse -cells. To quantify this decline in individual -cell
insulin content, we found that nondiabetic mouse -cell
insulin staining was 
30-fold greater than nonspeciﬁc
cellular ﬂuorescence, whereas recently diabetic mice had
only 
10-fold higher insulin-positive staining over back-
ground (Fig. 2C). This phenomenon was previously sus-
pected (22) but could not be objectively quantiﬁed using
conventional immunoﬂuorescence.
We also examined the fate of other endocrine cell
subsets in both healthy naïve mice (Fig. 3A–C) and in mice
with recent-onset diabetes (Fig. 3D–F). As expected,
healthy naïve Rip-CD80
GP
 bitransgenic mice closely
resembled C57BL/6 mice, both by immunoﬂuorescence
(Fig. 3A and B) and by ﬂow cytometry (Fig. 3C). In
contrast, heavily immune cell-inﬁltrated islets from dia-
betic Rip-CD80
GP
 mice revealed a distorted picture
(Fig. 3E–F). Because the islets were inﬁltrated with mono-
nuclear immune cells, the endocrine cells were reduced in
number and scattered (Fig. 3E). We were surprised to
observe, however, that the residual endocrine cell fre-
quency (suggested by immunoﬂuorescence and quantiﬁed
by ﬂow cytometry) (Fig. 3F) was not consistent with a
selective insulin-positive -cell loss. Rather, glucagon-
positive -cell numbers decreased commensurate with the
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FIG. 2. Diabetic mouse -cell optical changes by ﬂow cytometry. A:
Light scatter properties (cell size, forward light scatter [FSC]; and
granularity, side light scatter [SSC]) of dissociated islet cells (red,
-cells; green, -cells; blue, -cells) from naïve and diabetic mice are
shown. -Cell size distribution differs between naïve and diabetic mice.
B: Granularity (SSC) properties of naïve (gray) and diabetic (red) islet
cells gated on insulin-stained cells, displayed by histogram overlay, and
quantiﬁed by median side light scatter signal. C: Insulin-staining
brightness (median ﬂuorescence intensity) of naïve (gray) and dia-
betic (red) -cells is compared and plotted by histogram overlay and
fold increase over non–insulin-positive islet cells (background stain-
ing). ins, insulin-positive. (A high-quality digital representation of
this ﬁgure is available in the online issue.)
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pected to ﬁnd the insulin-positive–to–glucagon-positive
cell ratio substantially reduced in diabetic mice, the cell
ratio calculated using the ﬂow cytometry technique often
increased, suggesting that glucagon-positive cell numbers
fell even more than insulin-positive cell numbers.
Previous reports using immunohistochemistry to study
the pancreas in rodents undergoing acute -cell injury,
e.g., after streptozotocin administration (23,24) or sponta-
neous autoimmune islet destruction (25–27), have sug-
gested that residual pancreatic endocrine cells in diabetic
animals are comprised primarily of glucagon-positive
and/or somatostatin-positive cells. All such studies, how-
ever, have evaluated mice with near “end stage” diabetes,
whereas the EAD model allows us to better control both
the initiation and the kinetics of the -cell killing. We used
several independent techniques to comprehensively exam-
ine pancreatic endocrine cell composition in EAD mice
with recent-onset diabetes. As shown in Fig. 4A and B,w e
determined insulin-positive–to–glucagon-positive cell ra-
tios from naïve and diabetic mice by ﬂow cytometry and
by immunoﬂuorescence. Dissociated islet cells isolated
from healthy control animals then analyzed by ﬂow cytom-
etry had a ratio of 4.9 (n 
 9), which was comparable to
immunoﬂuorescence histology (4.7, n 
 3). In contrast,
islets analyzed from diabetic animals revealed a markedly
increased ratio when analyzed by ﬂow cytometry (9.8, n 

11) compared with immunoﬂuorescence (4.2, n 
 9).
Although ﬂow cytometry determines relative frequen-
cies of islet cell subsets with high ﬁdelity, its translation
into absolute cell numbers per pancreas has not been
possible. Therefore, we used quantitative immunohisto-
chemistry on multiple sections throughout the whole
pancreas in recently diabetic mice to determine changes in
absolute - and -cell numbers at diabetes onset. As
shown in Fig. 4C, recently diabetic Rip-CD80
GP
 bitrans-
genic mice revealed the expected -cell loss (an approxi-
mate 76% decrease relative to the healthy control animals)
but also a corresponding depletion of -cells (73% de-
crease) (Fig. 4D); each change is statistically signiﬁcant
(P  0.001). To test whether the observed -cell loss was
unique to our EAD model, we extended our study to
include the NOD mouse. As shown in Fig. 4C and D,a
comparable pattern was observed in pancreas sections
from newly diabetic NOD mice (age of diabetes onset:
18.2 	 1.8 weeks) when compared with similarly aged
female NOD-Rag1 null mice (13.4 weeks). Notably, how-
ever, nondiabetic NOD mice had about half as many total
- and -cells compared with the Rip-CD80
GP
 bitrans-
genic mice, and at diabetes onset, the NOD mice were
more severely -cell–depleted than EAD mice. That is,
diabetic NOD mice had lost 90% of their -cells (Fig. 4).
FIG. 3. Comparative analysis of naïve and diabetic pancreatic islets by immunoﬂuorescence and ﬂow cytometry. Islets from naïve (A–C) and
recently diabetic mice (D–F) were examined by tissue sectioning and hematoxylin and eosin staining (magniﬁcation 200) (A and D) and
three-color immunoﬂuorescence (magniﬁcation 400) (B and E). Typical islets are shown (A–B, D–E). In addition, islets from an individual naïve
or diabetic mouse were puriﬁed, dissociated, and analyzed by ﬂow cytometry (C and F). Flow cytometry results were normalized as in Fig. 1. F:
The drastically increased unstained cells (events shown in gray) represent cells within the islets that did not stain for any of the three islet
hormones, insulin, glucagon, or somatostatin, nor for the hematopoetic cell marker CD45, which had been excluded by electronic gating. Thus,
these cells represent islet cell components relatively enriched in inﬂamed, severe, endocrine cell–depleted islets. Note that the relative frequency
of insulin-positive cells did not decrease compared with glucagon-positive cells and, in this case, only marginally compared with somatostatin-
positive cells. Gcg, glucagon; Sst, somatostatin. (A high-quality digital representation of this ﬁgure is available in the online issue.)
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0.001). In the NOD mice, the -cell depletion was less
severe (58% or 2.4-fold) (Fig. 4D) and with P 
 0.026 did
not reach the same high statistical signiﬁcance we ob-
served in the EAD model. The greater -cell loss compared
with -cell loss in diabetic NOD mice resulted in a
moderately reduced insulin-positive–to–glucagon-positive
cell ratio (1.34 	 0.28, n 
 7). For instance, Fig. 5 shows
representative ﬂow cytometry analyses from islet cells
taken from diabetic (middle panels), nondiabetic (top
panels), and NOD-SCID mice (lower panels). We conclude
that both Rip-CD80
GP
 and NOD mice with severe
insulin deﬁciency caused by T-cell–mediated -cell killing
also lose many -cells, such that shortly after diabetes
onset, the insulin-positive–to–glucagon-positive cell ratio
is actually maintained or increased in many Rip-
CD80
GP
 mice and only moderately reduced in NOD
mice, despite a more profound -cell loss in the latter
strain.
Next, we asked whether this discrepancy could be
attributed, in part, to differential endocrine cell subset
distribution in large islets compared with smaller, sub–
islet-sized endocrine clusters that are scattered through-
out the pancreas. In the EAD model, during the
autoimmune process, such small endocrine cell clusters
are characteristically surrounded by a marked leukocytic
inﬁltration. We “scored” endocrine cells using immunoﬂu-
orescence microscopy (Fig. 6A) and arbitrarily grouped
the results into those from small clusters (30 endocrine
cells per islet cross section, which calculates to an islet
diameter as small as 50–70 m, depending on the level of
lymphocytic inﬁltration) and larger islets (30 endocrine
cells per islet). Although no difference in the insulin-
positive–to–glucagon-positive cell ratio was found in naïve
healthy pancreata from either C57BL/6 or Rip-CD80
GP

strains (Fig. 6A), pancreata from diabetic mice displayed a
substantial distortion; larger islets displayed an increased
insulin-positive–to–glucagon-positive cell ratio, whereas
small clusters had a decreased ratio (Fig. 6A). A quadratic
regression analysis comparing the endocrine cell ratio to
islet-size relationship is illustrated in more detail in sup-
plemental Fig. 2.
We reasoned that the discrepant results shown in Fig.
4A and B (i.e., greater insulin-positive–to–glucagon-posi-
tive dispersed diabetic islet cell ratio by ﬂow cytometry)
may have been caused by failure to collect and analyze the
exceedingly small, sub–islet-sized endocrine cell clusters
from pancreas digests for ﬂow cytometry. To test that
possibility, we used ﬂow cytometry to calculate the ratio
from conventionally puriﬁed islets and from an islet-
depleted, viable pancreas digest (Fig. 6B–G). Although the
ratio was comparable in naïve mice (Fig. 6B–D), diabetic
mice demonstrated a marked difference, with puriﬁed
islets displaying a higher ratio, whereas islet-depleted
pancreas digests had a decreased ratio (Fig. 6E–G). qRT-
PCR used to compare the insulin to glucagon mRNA from
puriﬁed islets and islet-depleted tissue conﬁrmed that the
puriﬁed islets lost at least as much glucagon compared
with insulin mRNA (supplemental Fig. 3). The lower
abundance of endocrine cells present in islet-depleted
pancreas digests suggests that the overall insulin-positive–
to–glucagon-positive cell ratio decrease reﬂects a more
precipitous (immune-mediated) -cell loss outside the
conﬁnes of traditionally recognized islets, rather than
increasing -cell number. For instance, as illustrated in
supplemental Fig. 4, we observed that single -cells or
small -cell clusters were harder to ﬁnd, were nearly
always surrounded by inﬂammatory immune cells in dia-
betic animals, and, unlike in the healthy pancreas, often
had glucagon-positive cells nearby.
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FIG. 4. Endocrine cell quantiﬁcation using ﬂow cytometry and quantitative immunohistochemistry. Pancreata from naïve (gray symbols) and
diabetic EAD mice (black symbols) were examined by multicolor ﬂow cytometry (A) and immunoﬂuorescence microscopy (B). Insulin-positive–
to–glucagon-positive cell ratios were plotted, with each symbol representing an individual mouse. Horizontal bars indicate the arithmetic means
for groups of mice; they were 4.9 and 9.8, respectively, for naïve and diabetic mice in panel A and 4.9 and 4.2, respectively, for panel B. Note that
puriﬁed, handpicked islets were used for ﬂow cytometry in A, whereas in B, all microscopically detectable insulin- or glucagon-stained cells were
scored. C: -Cell mass. D: -Cell mass from naïve (n  5) and diabetic (n  4) EAD mice (C and D, left side) and groups of age-matched NOD-Rag1
null (n  3) and diabetic NOD mice (n  4) (C and D, right side) were determined by image analysis of insulin or glucagon immunohistochemistry.
Each symbol represents the cumulative fractional cell mass per pancreas, and the error bars indicate the SEM of 3–7 individual sections per
pancreas. Differences in diabetic and naïve control pancreata were all found to be statistically signiﬁcant (P < 0.001, except for glucagon-positive
cell loss in NOD mice [P  0.026]). immunoﬂuor., immunoﬂuorescence.
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mice with recent-onset EAD did not establish a consistent
loss of -cells over -cells but, rather, revealed a broad
range of relative cell abundances (supplemental Table 1).
We therefore sought to examine individual mouse pancre-
ata in greater detail. To this end we examined random
pancreatic sections from naïve and diabetic EAD mice,
previously used for endocrine cell quantiﬁcation (Fig. 4B
and C). In naïve mice, we found the expected - and -cell
spatial orientation in islets and uniformly throughout the
organ (Fig. 7A–D). In contrast, the diabetic mouse pan-
creas analysis displayed marked differences, with two
distinct histopathological patterns occurring in the same
organ. The ﬁrst pattern was characterized by scarce,
scattered insulin-positive cells within inﬁltrated islets,
resulting in near parity of - and -cell numbers (Fig.
7E–H), which is a pattern consistent with an autoimmune
process that selectively destroyed most -cells but left
-cells unharmed. The second pattern revealed a similar
abundance of insulin-staining cells in severely inﬁltrated
islets along with dramatically reduced glucagon-stained
-cells (Fig. 7I–L), a ﬁnding not easily explained by a
-cell–speciﬁc deletion process. The two patterns were
not randomly distributed within the pancreas, but one or
the other pattern predominated in speciﬁc anatomical
lobes (or lobules), where the vast majority of islets tended
to show the same cell pattern.
Finally, we sought to address whether the observed
-cell loss might have a measurable functional corre-
late. We tested glucagon serum levels in both fed and
fasted mice and in response to 2-DG–induced intracel-
lular hypoglycemia. 2-DG was chosen over insulin-
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newly diabetic female NOD (middle panels), and 18-week-old NOD-SCID (lower panels) mice are shown. Gating strategy involved consecutive
light scatter (left column), exclusion of CD45-positive lymphocytes (center column), doublet exclusion (not shown), and relative frequencies of
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4 in both representative nondiabetic mice
(average -cell–to–-cell ratio was 3.4  0.5, n  7, and 4.0  0.2, n  3, respectively, for nondiabetic NOD and NOD-SCID mice) dropped to 1.8
in the diabetic NOD mouse (average for this group: 1.3  0.3, n  7) due to a more profound loss in the -cell compartment. Inﬁltrating
CD45-positive lymphocytes were absent in NOD-SCID islets, but plenty were found in isolated islets of both NOD mice, being more abundant in
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high-quality digital representation of this ﬁgure is available in the online issue.)
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suppress -cell glucagon secretion (28). Fed and over-
night-fasted glucagon levels were virtually unchanged
and indistinguishable in diabetic mice compared with
naïve control mice (Fig. 8). Remarkably, 2-DG–stimu-
lated glucagon secretion was signiﬁcantly blunted in the
diabetic mice (Fig. 8). 2-DG–induced glucagon response
could not have been inﬂuenced by elevated blood
glucose levels because the newly diabetic Rip-
CD80
GP
 mice (fed glucose 20 mmol/l) were re-
stored to normoglycemia after overnight fasting (mean
blood glucose 8.5 mmol/l and consistently negative for
fasting urine glucose) (Fig. 8), almost certainly reﬂect-
ing substantial residual -cell number at this early
disease time point. We cannot prove that the -cell loss
we observed at autoimmune diabetes onset and the

50% reduction of 2-DG–stimulated glucagon secretion
are causally related or whether -cell regulation of
glucagon mRNA and protein synthesis could be a con-
tributing factor. Further careful investigations including
-cell gene expression proﬁles and the application
of more sensitive organ perfusion approaches will likely
have to determine the exact cause of the glucagon
pathophysiology frequently observed in autoimmune
diabetes.
DISCUSSION
This study’s initial objective was to assess pancreatic
-cell numbers and physiology during immune-mediated
islet destruction by following the insulin-positive–to–glu-
cagon-positive cell ratios and other parameters made
possible by advanced ﬂow cytometry techniques. We were
surprised to observe that the relative frequency of the two
endocrine subsets consistently pointed to an unexpected
depletion of -cells, along with the expected -cell loss at
diabetes onset. It is important to point out that because the
ﬂow technique lacks an internal reference standard, one
cannot accurately determine the absolute number of -o r
-cells in the pancreas, only their relative proportion. We
therefore turned to immunoﬂuorescence microscopy and
quantitative immunohistochemistry, supported by qRT-
PCR, to provide additional, overlapping, and independent
techniques. As discussed in our results, all studies sup-
ported our initial conclusion that while -cells are being
depleted during autoimmune diabetes, many -cells also
disappear.
Several lines of thought make it unlikely that nonspe-
ciﬁc cell-mediated cytotoxicity (i.e., bystander injury)
caused the observed non–insulin-positive islet cell (i.e.,
-cell) depletion. First, the insulin promoter–controlled
FIG. 6. Quantiﬁcation of endocrine cells in large islets or sub–islet-sized endocrine clusters of. A: Relative abundance by immunoﬂuorescence
histology of - and -cells associated with islets or sub–islet-sized endocrine clusters in naïve and recently diabetic mice. Endocrine cells were
counted from sections and subdivided in groups of small–endocrine cell clusters (<30 endocrine cells per cross section, ) or large islets (>30
endocrine cells per cross section, u) and the sum of both (all islets, f). The insulin-positive–to–glucagon-positive cell ratio of naïve C57BL/6 (n 
3) and naïve and diabetic Rip-CD80
GP
 mice (n  3 and n  5, respectively) was plotted for each islet size group. Insulin-, glucagon-, and
somatostatin-positive cell frequencies were measured by ﬂow cytometry in different pancreas compartments and from both naïve and recently
diabetic mice. Puriﬁed islet cells (B and E) and viable, islet-depleted pancreatic tissue (C and F) were isolated from naïve (upper panels) and
diabetic mice (lower panels). Representative ﬂow cytometry plots and the calculated relative frequency of endocrine cell subsets are shown. D
and G: The averages of insulin-positive–to–glucagon-positive cell ratios among islets and islet-depleted tissue (containing the small endocrine
cell clusters) from healthy (n  4) (D) and diabetic mice (n  3) (G). depl., depleted; Gcg, glucagon; Ins, insulin; panc., pancreas. (A high-quality
digital representation of this ﬁgure is available in the online issue.)
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the adoptively transferred CTL (18,29), and transgenic
CD80 molecules, which are essential for diabetes induc-
tion, are expressed homogenously on the transgenic
mouse -cell surface but not on other islet cell types (4).
Whether all Rip-GP–transgenic -cells express the GP
transgene product is not known with certainty because
detecting GP by immunoﬂuorescence is hampered by
mixed intracytoplasmic and nuclear expression patterns
and by the limited availability of GP-speciﬁc antibodies.
That LCM virus infection efﬁciently induces fulminant
diabetes in Rip-GP mice (but never in wild-type controls)
(30) strongly suggests that the vast majority of -cells
express the antigen leading to their immune-mediated
destruction. In addition, the large proportion (30–70%) of
the activated -cell–monospeciﬁc TCR-transgenic CTLs
found in EAD model mouse islets at diabetes onset argues
in favor of a selective immune-targeting of the Rip-con-
trolled dominant GP epitope in -cells, and it does not
support T-cell epitope spreading as the underlying auto-
immune mechanism. Second, in past studies when we
cotransplanted islets expressing the GP along with wild-
type islets, only the GP-expressing -cells were destroyed,
despite an intense inﬂammatory inﬁltrate surrounding all
the islets. In this environment nontransgenic islets were
left microscopically intact and survived long-term (unpub-
lished results), arguing against an effective inﬂammation-
mediated bystander injury to -cells. Finally, we have
shown differential persistence of endocrine cells located
in islets verses sub–islet-sized endocrine cell clusters, as
well as very different endocrine cell ratios in anatomical
parts of the same pancreas, with no discernible differences
in the severity of immune cell inﬁltration. Taking all this
data together, we favor a scenario where -cell survival is
homeostatically regulated in the context of deteriorating
glycemia, possibly accompanied by regenerative pro-
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FIG. 7. Anatomical location within the pancreas determines the endocrine
cell fate during diabetes development. Consecutive sections of one naïve
(A–D) and one newly diabetic (E–L) Rip-CD80
GP
 mouse were analyzed
for insulin staining (left panels) and glucagon staining (right panels)b y
immunohistochemistry. The naïve pancreas showed the expected abundance
and spatial orientation of - and -cells in virtually all islets examined.
Representative islets (inset) are shown with higher magniﬁcation (Band D).
Groups of diabetic islets (arrowheads, depicted on glucagon-stained sections
only) are shown from different lobes of the same pancreas (E, G, I, and
K) and with higher magniﬁcation (F, H, J, and L). Note the uniform
pattern of endocrine islet cell abundance in neighboring groups of
islets. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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FIG. 8. Recently diabetic mice display lower secretory glucagon re-
sponses to 2-DG–induced intracellular (2-DG Ic) hypoglycemia. Blood
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GP
 mice were determined in random-fed mice
(n  7 and 4 for naïve and diabetic mice, respectively), in overnight-
fasted mice (n  16 and 8), and after 2-DG stimulation (n  15 and 7).
Serum glucagon levels are given as the means  SE. *P < 0.003.
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(e.g., pancreatic lobes) differently. It is also possible,
however, that within typically identiﬁed islets, -cell sur-
vival may be dependent upon a local -cell–associated
factor(s).
At diabetes onset, whereas insulin deﬁciency is axiom-
atic, abundant evidence suggests that pancreatic -cells
remain detectable for extended periods after disease diag-
nosis (31). It remains to be determined whether these
-cells persist after diabetes onset and/or are constantly
regenerated. Most notably, an endocrine cell regenerative
response has been reported to occur in several rodent
models by mechanisms involving both -cell proliferation
(32,33) and/or neogenesis (34). Regenerative processes
may be further stimulated in the presence of excess
glucose (1) and by extensive organ injury (22). Moreover,
neogenesis of insulin-producing cells by differentiation
from non–-cell precursors, such as ductal cells, could
explain the abundant and scattered immune cell inﬁltrates
we observe at diabetes onset, particularly inﬁltrates along
ductal structures, often distant from any recognizable islet
structure. Such regenerative neogenesis may partially or
entirely recapitulate embryonic islet cell development (35)
and differ among mouse strains. Thus, at present we can
only speculate about the possibility that an accelerated
-cell regenerative process stimulated by severe immune-
mediated -cell killing and deteriorating glycemia causes
a distorted distribution of those endocrine cells that are
not insulin positive, especially -cells. In this respect it is
important to note that type 1 diabetic patients (36), and
animals with autoimmune diabetes (37,38), are known
to display aberrant glucagon secretory patterns. For in-
stance, although fasting serum glucagon levels are usually
normal in type 1 diabetes, they paradoxically can increase
with overt hyperglycemia (39,40). Furthermore, many
patients with type 1 diabetes fail to counterregulate hypo-
glycemia with adequate glucagon secretion (41,42), remi-
niscent of our results demonstrating that “intracellular”
hypoglycemia-induced glucagon secretion is severely di-
minished in newly diabetic mice.
Our ﬁndings demonstrate that after autoimmune diabe-
tes onset an endocrine cell’s fate is dynamically regulated,
responding to its micro- and macroenvironment. We argue
that carefully unraveling the processes underlying autoim-
mune diabetes will illuminate pancreatic islet endocrine
cell subsets’ interdependence and may shed light on
regenerative functions—including islet cell replication and
neogenesis—that ultimately exhaust and fail, precipitating
the onset of autoimmune diabetes.
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